Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Disialoganglioside GD2 as a therapeutic target for human diseases

(2015) Maya Suzuki et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles

(2015) Dana C Baiu et al.   Nanomedicine

Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant

(2014) Hiroki Kawano et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma

(2014) M. Emmy M. Dolman et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma

(2014) X. Zhao et al.   MOLECULAR CANCER THERAPEUTICS

Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional Nanocarrier

(2014) Jianqin Lu et al.   MOLECULAR PHARMACEUTICS

Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation

(2014) Kohsuke Shakushiro et al.   PHARMACEUTICAL RESEARCH

Current and Future Strategies for Relapsed Neuroblastoma

(2013) Daniel A. Morgenstern et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways

(2013) Roy van der Meel et al.   MOLECULAR PHARMACEUTICS

Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or non-Hodgkin lymphoma

(2012) Yumiko Aoyama et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats

(2012) Tsuyoshi Minematsu et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Utility of P-Glycoprotein and Organic Cation Transporter 1 Double-Transfected LLC-PK1 Cells for Studying the Interaction of YM155 Monobromide, Novel Small-Molecule Survivin Suppressant, with P-Glycoprotein

(2011) M. Iwai et al.   DRUG METABOLISM AND DISPOSITION

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

(2011) Fieke Lamers et al.   ENDOCRINE-RELATED CANCER

Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression

(2011) Fieke Lamers et al.   EUROPEAN JOURNAL OF CANCER

Targeted drug delivery to tumors: Myths, reality and possibility

(2011) You Han Bae et al.   JOURNAL OF CONTROLLED RELEASE

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

(2010) M. Tanioka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

Survivin: A new target for anti-cancer therapy

(2009) Bríd M. Ryan et al.   CANCER TREATMENT REVIEWS

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

(2009) T. Satoh et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

The epidemiology of neuroblastoma: a review

(2008) Julia E. Heck et al.   PAEDIATRIC AND PERINATAL EPIDEMIOLOGY